Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Charles Schwab Investment Management Inc. lifted its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 152.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 314,265 shares of the biotechnology company's stock after buying an additional 189,727 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.56% of Astria Therapeutics worth $3,460,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics during the 1st quarter worth about $200,000. Bank of New York Mellon Corp raised its holdings in Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock worth $1,266,000 after purchasing an additional 8,965 shares during the last quarter. Panagora Asset Management Inc. raised its holdings in Astria Therapeutics by 104.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 15,816 shares during the last quarter. Rhumbline Advisers raised its holdings in Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock worth $595,000 after purchasing an additional 2,556 shares during the last quarter. Finally, Quest Partners LLC raised its holdings in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,112 shares during the last quarter. 98.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on ATXS shares. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $25.60.

Astria Therapeutics Price Performance

Shares of Astria Therapeutics stock traded down $0.29 during trading on Friday, hitting $9.52. 195,675 shares of the company were exchanged, compared to its average volume of 593,820. The firm has a market capitalization of $537.21 million, a P/E ratio of -4.56 and a beta of 0.67. Astria Therapeutics, Inc. has a 1-year low of $5.80 and a 1-year high of $16.90. The firm's fifty day moving average price is $10.82 and its 200 day moving average price is $10.70.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.